158 related articles for article (PubMed ID: 20391956)
21. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
Silvestri B; Bandieri E; Del Prete S; Ianniello GP; Micheletto G; Dambrosio M; Sabbatini G; Endrizzi L; Marra A; Aitini E; Calorio A; Garetto F; Nastasi G; Piantedosi F; Sidoti V; Spanu P
Clin Drug Investig; 2008; 28(7):399-407. PubMed ID: 18544000
[TBL] [Abstract][Full Text] [Related]
22. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.
Gatti A; Sabato AF; Occhioni R; Colini Baldeschi G; Reale C
Eur Neurol; 2009; 61(3):129-37. PubMed ID: 19092248
[TBL] [Abstract][Full Text] [Related]
23. Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe postherpetic neuralgia pain.
Fan BF;
Oncology; 2008; 74 Suppl 1():66-71. PubMed ID: 18758201
[TBL] [Abstract][Full Text] [Related]
24. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
25. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Hagen NA; Babul N
Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
[TBL] [Abstract][Full Text] [Related]
26. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
27. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial.
Marco CA; Plewa MC; Buderer N; Black C; Roberts A
Acad Emerg Med; 2005 Apr; 12(4):282-8. PubMed ID: 15805317
[TBL] [Abstract][Full Text] [Related]
28. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
29. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
[TBL] [Abstract][Full Text] [Related]
30. Codeine and oxycodone use in patients with chronic rheumatic disease pain.
Ytterberg SR; Mahowald ML; Woods SR
Arthritis Rheum; 1998 Sep; 41(9):1603-12. PubMed ID: 9751092
[TBL] [Abstract][Full Text] [Related]
31. [Rating of opioids. With rational use for individual treatment goal].
MMW Fortschr Med; 2006 Aug; 148(35-36):54. PubMed ID: 16995369
[No Abstract] [Full Text] [Related]
32. [Controlled release oxycodone--a new option in the treatment of severe and very severe pain. Review of studies on neuropathic, physical activity-related and postoperative pain].
Stiehl M
MMW Fortschr Med; 2004 Aug; 146 Suppl 2():61-9. PubMed ID: 16739361
[TBL] [Abstract][Full Text] [Related]
33. Oxycodone. Pharmacological profile and clinical data in chronic pain management.
Coluzzi F; Mattia C
Minerva Anestesiol; 2005; 71(7-8):451-60. PubMed ID: 16012419
[TBL] [Abstract][Full Text] [Related]
34. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
35. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
36. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
37. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
Miner JR; Moore J; Gray RO; Skinner L; Biros MH
Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
[TBL] [Abstract][Full Text] [Related]
38. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study.
Gatti A; Longo G; Sabato E; Sabato AF
Eur Neurol; 2011; 65(6):317-22. PubMed ID: 21576968
[TBL] [Abstract][Full Text] [Related]
39. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
Junker U; Figge V
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
[TBL] [Abstract][Full Text] [Related]
40. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
